Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #2813125

Concept 2022-01-01 to
2022-12-31
2021-01-01 to
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Increase (decrease) in working capital
3 142 EUR
1 025 EUR
Adjustments for increase (decrease) in other liabilities
234,000 EUR
Adjustments for decrease (increase) in other current assets
1 323 EUR
Adjustments for increase (decrease) in employee benefit liabilities
147,000 EUR
78,000 EUR
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
6,000 EUR
0 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.